Histopathological lesions | All IAR (n=21) | Age at Dx (years) | FPC2 (n=7) | FPC3 (n=11) | IAR with PALB2 or BRCA2 mutations (n=3) |
---|---|---|---|---|---|
PDAC | 2 | 53*, 68+ | 1 | 1 | |
pNET | 1 | 48^ | 1 | ||
Multifocal PanIN2+PanIN3 | 3 | 52*, 64*, 69* | 1 | 2 | |
BD-IPMN with HGD | 1 | 52+ | 1 | ||
Multifocal PanIN2+ BD-IPMN with LGD/MGD±AFL | 6 | 47+, 54+, 57, 58*, 61, 70* | 1 | 4 | 1 |
Multifocal PanIN2 | 2 | 53°, 67+ | 1 | 1 | |
Focal fibrosis+PanIN1b | 3 | 49^, 54°, 60° | 1 | 2 | |
Serous cystadenoma | 3 | 42°, 61°, 61° | 2 | 1 |
Superscripts indicate previous references that reported imaging and pathological results of IAR: +-17; *-16, 17; ^-17, 20; °-8, 16, 17.
FPC2, two affected first-degree relatives; FPC3, at least three affected relatives.
AFL, atypical flat lesion; BD-IPMN, branch-duct type intrapapillary mucinous neoplasia; FPC, familial pancreatic cancer; IAR, individuals at risk; LGD/MGD/HGD, low-grade, moderate-grade, high-grade dysplasia; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.